Citadel Advisors
DYN icon

Citadel Advisors’s Dyne Therapeutics DYN Stock Holding History

Citadel Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.4M Buy
1,143,958
+942,814
+469% +$17.5M ﹤0.01% 2280
2026
Q1 		$3.65M Sell
201,144
-970,480
-83% -$16.7M ﹤0.01% 4884
2025
Q4 		$22.9M Sell
1,171,624
-2,241,811
-66% -$42.5M ﹤0.01% 2188
2025
Q3 		$43.2M Buy
3,413,435
+2,469,561
+262% +$28.2M 0.01% 1537
2025
Q2 		$8.99M Sell
943,874
-2,065,515
-69% -$22.7M ﹤0.01% 3184
2025
Q1 		$31.5M Buy
3,009,389
+147,808
+5% +$2.11M 0.01% 1543
2024
Q4 		$67.4M Sell
2,861,581
-77,759
-3% -$2.3M 0.01% 1020
2024
Q3 		$106M Sell
2,939,340
-1,376,666
-32% -$54.8M 0.02% 664
2024
Q2 		$152M Buy
4,316,006
+61,730
+1% +$1.79M 0.03% 462
2024
Q1 		$121M Buy
4,254,276
+1,200,836
+39% +$27.2M 0.02% 595
2023
Q4 		$40.6M Buy
3,053,440
+11,834
+0.4% +$116K 0.01% 1346
2023
Q3 		$27.3M Buy
3,041,606
+335,603
+12% +$3.61M 0.01% 1579
2023
Q2 		$30.4M Sell
2,706,003
-322,797
-11% -$3.81M 0.01% 1460
2023
Q1 		$34.9M Buy
3,028,800
+118,721
+4% +$1.54M 0.01% 1400
2022
Q4 		$33.7M Sell
2,910,079
-12,293
-0.4% -$142K 0.01% 1446
2022
Q3 		$37.1M Sell
2,922,372
-3,342
-0.1% -$38.3K 0.01% 1299
2022
Q2 		$20.1M Sell
2,925,714
-36,619
-1% -$252K 0.01% 1850
2022
Q1 		$28.6M Buy
2,962,333
+98,133
+3% +$836K 0.01% 1596
2021
Q4 		$34.1M Sell
2,864,200
-9,477
-0.3% -$133K 0.01% 1496
2021
Q3 		$46.7M Sell
2,873,677
-42,837
-1% -$759K 0.01% 1192
2021
Q2 		$61.4M Sell
2,916,514
-179,066
-6% -$3.37M 0.01% 968
2021
Q1 		$48.1M Sell
3,095,580
-68,740
-2% -$1.33M 0.01% 1074
2020
Q4 		$66.5M Buy
3,164,320
+195,927
+7% +$3.88M 0.02% 771
2020
Q3 		$59.9M Buy
+2,968,393
New +$65.1M 0.02% 742

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citadel Advisors's DYN Position: Q2 2026 in Review

Citadel Advisors increased its Dyne Therapeutics (DYN) stake by 469% in Q2 2026, buying an estimated $17.5M and bringing the position to 1,143,958 shares worth $25.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2280.

Citadel Advisors first reported a position in DYN in Q3 2020 and has held it in 24 quarters since. The position peaked at $152M in Q2 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Citadel Advisors held 1,143,958 shares of Dyne Therapeutics worth $25.4M as of Q2 2026.
  • Citadel Advisors bought 942,814 Dyne Therapeutics shares in Q2 2026, an estimated $17.5M.
  • Dyne Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2280 holding.
  • Citadel Advisors first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Dyne Therapeutics position peaked at $152M in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.